文献速递糖尿病

德谷胰岛素与甘精胰岛素U300在胰岛素治疗的2型糖尿病患者中的低血糖风险:随机头对头CONCLUDE试验

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
PubMed 文献 · Diabetologia · 2020-01-27

CONCLUDE是一项随机、开放标签、 multinational、达标治疗试验,纳入1609例接受基础胰岛素治疗的2型糖尿病患者,比较德谷胰岛素U200与甘精胰岛素U300的低血糖风险。维持期主要终点总体症状性低血糖发生率两组无显著差异(RR 0.88 [95% CI 0.73, 1.06]),因主要终点无显著差异,优效性验证程序终止;预设的确认性次要终点改为探索性分析,显示德谷胰岛素U200组夜间症状性低血糖(RR 0.63 [95% CI 0.48, 0.84])和严重低血糖(RR 0.20 [95% CI 0.07, 0.57])发生率较低。

要点

  • 维持期总体症状性低血糖发生率德谷U200组与甘精U300组无显著差异(RR 0.88 [95% CI 0.73, 1.06])。
  • 因主要终点无显著差异,优效性验证程序终止,确认性次要终点改为探索性分析。
  • 探索性分析显示德谷U200组夜间症状性低血糖(RR 0.63 [95% CI 0.48, 0.84])和严重低血糖(RR 0.20 [95% CI 0.07, 0.57])发生率较低。

核心结论

  • 维持期德谷胰岛素U200与甘精胰岛素U300的总体症状性低血糖发生率无显著差异。
  • 维持期德谷胰岛素U200组夜间症状性低血糖和严重低血糖发生率名义上显著低于甘精胰岛素U300组。

研究设计与样本

  • 随机(1:1)、开放标签、达标治疗、跨国试验,纳入年龄≥18岁、HbA1c≤80 mmol/mol(9.5%)、BMI≤45 kg/m2的2型糖尿病患者。
  • 参与者既往接受基础胰岛素治疗,伴或不伴口服降糖药(排除胰岛素促泌剂),且至少满足一项预设的低血糖风险标准。
  • 德谷胰岛素U200与甘精胰岛素U300均滴定至空腹血糖目标4.0-5.0 mmol/l。
  • 共随机1609例参与者,德谷U200组805例中733例(91.1%)完成试验,甘精U300组804例中734例(91.3%)完成试验(按治疗完成分别为87.3%和87.8%)。
  • 终点在36周维持期和最长88周总治疗期内评估。

主要发现

  • 主要终点:维持期总体症状性低血糖发生率德谷U200组与甘精U300组相比无显著降低(RR 0.88 [95% CI 0.73, 1.06])。
  • 因主要终点无显著差异,优效性确认检验程序终止;预设的确认性次要低血糖终点改用预设统计模型分析,但现视为探索性。
  • 探索性分析显示,维持期夜间症状性低血糖发生率德谷U200组低于甘精U300组(RR 0.63 [95% CI 0.48, 0.84])。
  • 探索性分析显示,维持期严重低血糖发生率德谷U200组低于甘精U300组(RR 0.20 [95% CI 0.07, 0.57])。

关键数值与推荐

  • 总体症状性低血糖定义:严重事件、需第三方协助的事件,或血糖<3.1 mmol/l伴症状的确认事件。
  • 夜间症状性低血糖定义:严重事件或血糖确认伴症状的事件,发生于00:01至05:59。
  • 严重低血糖为第三项低血糖终点。
  • 主要终点为维持期总体症状性低血糖事件数;次要终点包括维持期夜间症状性事件数和严重低血糖事件数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因主要终点无显著差异,优效性确认检验程序终止,预设的确认性次要低血糖终点改为探索性分析。
  • 次要终点结果应视为探索性,原文使用「名义上显著」描述夜间症状性和严重低血糖的组间差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: A head-to-head randomised trial was conducted to evaluate hypoglycaemia safety with insulin degludec 200 U/ml (degludec U200) and insulin glargine 300 U/ml (glargine U300) in individuals with type 2 diabetes treated with basal insulin. METHODS: This randomised (1:1), open-label, treat-to-target, multinational trial included individuals with type 2 diabetes, aged ≥18 years with HbA1c ≤80 mmol/mol (9.5%) and BMI ≤45 kg/m2. Participants were previously treated with basal insulin with or without oral glucose-lowering drugs (excluding insulin secretagogues) and had to fulfil at least one predefined criterion for hypoglycaemia risk. Both degludec U200 and glargine U300 were similarly titrated to a fasting blood glucose target of 4.0-5.0 mmol/l. Endpoints were assessed during a 36 week maintenance period and a total treatment period up to 88 weeks. There were three hypoglycaemia endpoints: (1) overall symptomatic hypoglycaemia (either severe, an event requiring third-party assistance, or confirmed by blood glucose [<3.1 mmol/l] with symptoms); (2) nocturnal symptomatic hypoglycaemia (severe or confirmed by blood glucose with symptoms, between 00:01 and 05:59 h); and (3) severe hypoglycaemia. The primary endpoint was the number of overall symptomatic hypoglycaemic events in the maintenance period. Secondary hypoglycaemia endpoints included the number of nocturnal symptomatic events and number of severe hypoglycaemic events during the maintenance period. RESULTS: Of the 1609 randomised participants, 733 of 805 (91.1%) in the degludec U200 arm and 734 of 804 (91.3%) in the glargine U300 arm completed the trial (87.3% and 87.8% completed on treatment, respectively). Baseline characteristics were comparable between the two treatment arms. For the primary endpoint, the rate of overall symptomatic hypoglycaemia was not significantly lower with degludec U200 vs glargine U300 (rate ratio [RR] 0.88 [95% CI 0.73, 1.06]). As there was no significant difference between treatments for the primary endpoint, the confirmatory testing procedure for superiority was stopped. The pre-specified confirmatory secondary hypoglycaemia endpoints were analysed using pre-specified statistical models but were now considered exploratory. These endpoints showed a lower rate of nocturnal symptomatic hypoglycaemia (RR 0.63 [95% CI 0.48, 0.84]) and severe hypoglycaemia (RR 0.20 [95% CI 0.07, 0.57]) with degludec U200 vs glargine U300. CONCLUSIONS/INTERPRETATION: There was no significant difference in the rate of overall symptomatic hypoglycaemia with degludec U200 vs glargine U300 in the maintenance period. The rates of nocturnal symptomatic and severe hypoglycaemia were nominally significantly lower with degludec U200 during the maintenance period compared with glargine U300. TRIAL REGISTRATION: ClinicalTrials.gov NCT03078478 FUNDING: This trial was funded by Novo Nordisk (Bagsvaerd, Denmark).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Philis-Tsimikas A, Klonoff DC, Khunti K, et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial. Diabetologia. 2020. PMID: 31984443. doi:10.1007/s00125-019-05080-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。